The urgency behind the effort is easy to grasp. Intrahepatic cholangiocarcinoma accounts for roughly 8 to 15 percent of all primary malignant liver tumors, second only to hepatocellular carcinoma, and its incidence has been climbing. Five-year overall survival sits at approximately nine percent. Surgery remains the only curative option, yet 70 to 80 percent of patients arrive at the clinic with disease that is either locally unresectable or already metastatic. For them, systemic therapy can delay progression but typically extends survival to only about a year. Against that grim backdrop, the discovery that roughly 40 to 50 percent of these tumors carry actionable genetic alterations has transformed the conversation, turning molecular profiling from an academic exercise into a clinical necessity.

The guideline, developed under the auspices of the Chinese Anti-Cancer Association’s liver cancer and pathology societies with international co-authors from Singapore, Australia, the United States and China, was registered on a transparency platform for practice guidelines and graded its evidence using the GRADE system. Its central message is blunt: molecular testing is recommended for all patients with intrahepatic cholangiocarcinoma, and it is essential for those with unresectable or metastatic disease, because the tumor’s genetic landscape differs markedly from that of extrahepatic bile duct cancers and gallbladder cancers, and even different pathological subtypes of the tumor behave differently at the DNA level.

At the top of the target list sits FGFR2, a receptor tyrosine kinase gene that is rearranged or fused in between 6.6 and 20 percent of Chinese patients with the disease, particularly in the small-duct subtype. These fusions typically break the gene between exons 17 and 19, leaving the receptor’s kinase domain intact while deleting regulatory elements that normally switch the receptor off, resulting in constitutive growth signaling. More than 140 partner genes have been identified, with BICC1 the most frequent. Two drugs, pemigatinib and futibatinib, are now approved by regulators in the United States and China for previously treated patients whose tumors harbor FGFR2 fusions, and both are recommended as second-line options in major treatment guidelines.

Choosing the right detection method for FGFR2 turns out to matter enormously, and the consensus devotes unusual technical detail to the question. Fluorescence in situ hybridization with break-apart probes can flag rearrangements but cannot identify fusion partners and may miss closely spaced intrachromosomal events. DNA-based next-generation sequencing can simultaneously detect mutations, amplifications and fusions across many genes, but it cannot confirm that a detected fusion actually produces a functional RNA transcript. RNA-based sequencing, by contrast, provides direct evidence of functional fusions and can uncover novel partners, with concordance between the two sequencing approaches reaching 98 percent. The panel therefore recommends combining DNA- and RNA-based sequencing, reserving FISH as a fallback when sequencing is unavailable, and explicitly discourages FGFR2 immunohistochemistry, which shows poor agreement with molecular methods. In a striking practical touch, the guideline even borrows interpretation thresholds from ALK testing in lung cancer, since no standardized cutoff for FGFR2 break-apart positivity exists.

A second pillar of the guideline concerns IDH1, a metabolic enzyme whose mutations occur in 4.9 to 20 percent of Chinese patients, again concentrated in the small-duct subtype. The inhibitor ivosidenib received United States approval in 2021 for previously treated, IDH1-mutant cholangiocarcinoma, with a companion diagnostic test cleared alongside it. Mutations cluster at position 132, most commonly R132C, a detail with real diagnostic consequences: the commercial immunohistochemistry antibody targets the R132H variant common in gliomas and cannot recognize R132C, limiting staining’s usefulness here. Sequencing, preferably by next-generation platforms that can capture multiple loci, is the preferred route, and the panel notes that secondary resistance mutations such as D279N, or oncogenic IDH2 mutations like R172K, can emerge under treatment pressure, making comprehensive sequencing valuable even after therapy begins.

The guideline then marches through a roster of additional targets. BRAF V600E, present in a subset of the 4.2 percent of Chinese patients with BRAF mutations, is sensitive to the approved dabrafenib-plus-trametinib combination, while non-V600 variants respond to MEK inhibitors but not BRAF inhibitors, so the panel urges attention beyond the flagship site. HER2 overexpression and ERBB2 amplification, found in 1.8 to 8 percent of patients, open doors to trastuzumab-based regimens including trastuzumab deruxtecan, with immunohistochemistry prioritized and equivocal cases confirmed by FISH or sequencing, interpreted for now by adapting breast and gastric cancer criteria. Rarer but druggable alterations receive their due as well: NTRK fusions in under one percent of patients, RET fusions in 1.8 percent, KRAS mutations in 12.4 to 25 percent, and NRG1 fusions in roughly two percent, each with preferred platforms, mostly RNA-based sequencing for fusions and broad DNA panels for point mutations.

Immune checkpoint eligibility also earns a formal recommendation. Deficient mismatch repair or high microsatellite instability, present in 1.6 to 6 percent of Chinese patients, predicts response to immunotherapy, and several checkpoint inhibitors are approved for such tumors in both the United States and China. The panel endorses mismatch repair immunohistochemistry or polymerase chain reaction-based microsatellite testing as primary methods, and adds a cautionary note drawn from a study of 1,942 solid tumors: sequencing-based microsatellite calls are fully concordant with conventional methods only at the extremes, so borderline results must be validated by immunohistochemistry or PCR before treatment decisions rest on them.

Equally pragmatic are the recommendations about samples themselves. Because intrahepatic cholangiocarcinoma is stroma-rich, tumor cell content in biopsies is often low; in one series of 123 advanced biliary tract cancers, more than a quarter of samples were unsuitable for sequencing due to insufficient tumor content. The consensus requires pathologists to verify at least 20 percent tumor cellularity and a minimum of 50 tumor cells before testing, and urges clinicians to obtain enough tissue in a single procedure for both diagnosis and molecular workup. Tissue remains the gold standard, with cytology cell blocks as the fallback and liquid biopsy of circulating tumor DNA as a last resort at accredited laboratories, since concordance between blood and tissue varies dramatically, from 87 to 100 percent for point mutations down to just 18 percent for FGFR2 fusions. Primary lesions are preferred for initial testing, though metastatic sites may be sampled when the primary is inaccessible, and repeat biopsy after progression on targeted therapy is explicitly encouraged to map resistance mechanisms.

The panel closes by sorting biomarkers into essential and optional categories, the latter including emerging targets such as PTEN loss, Claudin 18.2 expression and BRCA1/2 mutations that may guide trial enrollment, and it commits to periodic revisions as new drugs and data accumulate. For a cancer with a nine percent five-year survival rate, the stakes of getting testing right could hardly be higher. What this guideline offers is a shared playbook: a single, evidence-graded document telling laboratories and clinicians worldwide which genes to interrogate, which platforms to trust, how to interpret ambiguous signals, and when to re-biopsy, so that every patient with this aggressive tumor has the best possible chance of finding a therapy matched to the specific molecular engine driving their disease.

Subject of Research: Precision molecular biomarker testing guidelines for intrahepatic cholangiocarcinoma

Article Title: Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensus

Article References: Zhang, X., Han, J., Shi, R., Yu, B., Zhang, X., Li, B., Sheng, X., Li, Z., Zou, Y., Sun, H., Shi, G., Wang, H. L., Zhou, J., Fan, J., Cong, W., & Ji, Y. (2025). Guideline of precisional testing in intrahepatic cholangiocarcinoma: an international expert consensus. Clinical Cancer Bulletin, 4(1), Article 9. https://doi.org/10.1007/s44272-025-00036-0

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00036-0

Keywords: intrahepatic cholangiocarcinoma, molecular testing, FGFR2 fusions, IDH1 mutations, next-generation sequencing, targeted therapy, biomarkers, precision oncology, bile duct cancer, HER2, microsatellite instability, expert consensus

The study, led by Feng Li and Wenfeng Zhang along with colleagues in China, rests on a deceptively simple biological premise: cancer is not just a disease of uncontrolled growth, but of rewired metabolism. Tumor cells undergo metabolic reprogramming, altering how they consume glucose, synthesize lipids, and process amino acids to fuel their expansion. The genes that govern these processes, collectively termed metabolism-related genes, sit upstream of many of the changes clinicians currently measure. The authors argue that shifts in these regulatory genes precede changes in established tumor markers such as carbohydrate antigen 19-9, carcinoembryonic antigen, and lactic acid, making them potentially more sensitive and reliable indicators of disease course.

To test this idea, the team mined the Kyoto Encyclopedia of Genes and Genomes database for a comprehensive catalog of 3,216 metabolism-related genes. They then compared the expression of these genes between normal liver tissue and intrahepatic cholangiocarcinoma specimens using the TCGA-CHOL collection, which provided mRNA profiles and clinical data for 32 tumor samples and 8 normal controls. Rigorous statistical filtering, employing the limma framework with a false discovery rate threshold below 0.01 and absolute log2 fold changes exceeding 2, revealed a striking landscape of metabolic disruption: 1,002 differentially expressed metabolic genes, of which 717 were elevated and 285 were suppressed in tumors. Hierarchical clustering showed that these expression patterns alone were sufficient to cleanly separate cancerous from healthy tissue.

Functional enrichment analysis added biological texture to the numbers. Gene Ontology and KEGG pathway analyses indicated that the dysregulated genes clustered around the metabolism and synthesis of energy-bearing substances, catalytic activity, the chemical carcinogenesis pathway, and signaling through peroxisome proliferator-activated receptors, or PPARs. That last finding is particularly intriguing given prior evidence that PPARγ can suppress cholangiocarcinoma growth through p53-dependent pathways and that a microRNA targeting PPARγ contributes to gemcitabine resistance. The enrichment results suggest that metabolic gene dysregulation in this cancer is not random noise but converges on pathways with known roles in tumor initiation and treatment failure.

The next challenge was to compress more than a thousand candidate genes into a clinically usable predictor. The researchers first applied univariate Cox regression with a stringent significance threshold of p less than 0.005, which flagged six genes associated with elevated mortality risk: SLC16A3, B4GALNT1, ACSL4, MTHFD1L, PYGB, and AGPAT4. They then turned to LASSO Cox regression, a machine-learning technique that shrinks the coefficients of less informative variables toward zero to guard against overfitting in small datasets. With three-fold cross-validation and an optimal penalty parameter of 0.1196, the model settled on four genes. The resulting risk score is a weighted sum of their expression levels, with MTHFD1L carrying the largest coefficient at 0.059857, followed by ACSL4, PYGB, and SLC16A3.

The performance of this compact signature was remarkable. When patients in the TCGA cohort were split into high-risk and low-risk groups at the median score, Kaplan-Meier analysis showed dramatically worse overall survival in the high-risk category. More striking still, receiver operating characteristic analysis yielded an area under the curve of 0.994 for the risk score, dwarfing the predictive power of age (0.819), sex (0.623), histological grade (0.609), pathologic stage (0.545), and nodal or metastatic staging, which fell below 0.5. In both univariate and multivariate Cox regression, the risk score was the only factor significantly associated with overall survival, marking it as an independent prognostic variable rather than a proxy for tumor burden.

Crucially, the model survived contact with external data. In an independent validation cohort of 30 patients from the GEO database (dataset GSE107943), high-risk patients again died at markedly higher rates, and the risk score achieved an area under the curve of 0.789, the best among all tested variables. In this cohort, only vascular invasion and the risk score emerged as significant predictors in multivariate analysis. Subgroup analyses reinforced the biological plausibility of the signature: patients with better-prognosis molecular subclass A tumors showed significantly lower expression of MTHFD1L, SLC16A3, and PYGB, and correspondingly lower risk scores, than those in the poorer-prognosis subclass B.

The team did not stop at computational modeling. Quantitative reverse transcription polymerase chain reaction confirmed that all four genes were expressed at significantly higher levels in two cholangiocarcinoma cell lines, CCLP1 and HuCCT-1, than in immortalized normal biliary epithelial cells. Immunohistochemical data from the Human Protein Atlas showed that the proteins SLC16A3, ACSL4, and PYGB were also elevated in tumor tissue, while MTHFD1L protein was paradoxically lower in tumors despite elevated mRNA, a discrepancy the authors acknowledge and that may reflect post-transcriptional regulation. Each gene carries mechanistic intrigue: SLC16A3, a lactate transporter, is co-activated by mutant KRAS and CK2 to drive tumor progression; ACSL4 participates in ferroptosis, an iron-dependent form of cell death; MTHFD1L is a folate-cycle enzyme implicated in hepatocellular carcinoma; and PYGB, brain-type glycogen phosphorylase, fuels aerobic glycolysis. Notably, PYGB expression showed the strongest and most consistent association with survival across both cohorts, and prior work has shown that inhibiting PYGB slows cholangiocarcinoma progression by reprogramming glycolysis, making it a compelling therapeutic target.

The authors are candid about limitations. The training and validation cohorts were small, retrospective, and drawn from public repositories, and bulk transcriptomic data are vulnerable to technical and biological confounding. Prospective validation in larger, randomized populations or patient-derived xenograft models will be essential before the signature can inform clinical decisions. Even so, the study delivers what the field has lacked: a parsimonious, independently validated metabolic gene model that surpasses traditional staging in predictive accuracy. If larger trials confirm its performance, the four-gene score could help clinicians identify high-risk patients earlier, stratify them for intensified therapy, and, through targets like PYGB and SLC16A3, open new pharmacological avenues in a cancer that urgently needs them.

Subject of Research: A metabolism-related gene signature for predicting prognosis in intrahepatic cholangiocarcinoma

Article Title: A new predictive model for intrahepatic cholangiocarcinoma based on metabolism-related genes

Article References: Li, F., Su, D., Deng, X., Wang, M., Tan, J., Chen, B., He, W., Miao, C., & Zhang, W. (2026). A new predictive model for intrahepatic cholangiocarcinoma based on metabolism-related genes. Heliyon, 12(15), Article e45494. https://doi.org/10.1016/j.heliyon.2026.e45494

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45494

Keywords: intrahepatic cholangiocarcinoma, metabolic reprogramming, prognostic model, LASSO Cox regression, PYGB, SLC16A3, ACSL4, MTHFD1L, biomarker, TCGA, gene expression, liver cancer

The research team, led by Kaisi Yang and corresponding authors Yingshi Zhang and Qingchun Zhao, working across Shenyang Pharmaceutical University, the General Hospital of Northern Theater Command, and Wannan Medical University Affiliated Tongling People’s Hospital, assembled a multi-layered case for ADAM8/17’s involvement in this cancer. Their investigation began with bioinformatic mining of publicly available gene expression datasets, which revealed that ADAM8 is highly and specifically overexpressed in intrahepatic cholangiocarcinoma compared with surrounding tissue and other tumor types. This pattern of selective elevation is exactly what drug developers look for in a target: a molecule that is abundant in the disease but dispensable elsewhere, minimizing the risk of collateral toxicity.

Correlation alone, however, has long been a trap in cancer genomics. Many genes are merely passengers that ride along with tumor progression without causing it. To address this, the team turned to Mendelian randomization, a statistical technique that uses naturally occurring genetic variants as instruments to test whether an exposure, in this case ADAM8/17 expression, plausibly causes a disease outcome rather than simply accompanying it. By combining two-sample Mendelian randomization analyses with a meta-analysis across independent datasets, the researchers found that genetically influenced ADAM8/17 activity and its downstream Notch signaling pathway were closely linked to the occurrence and development of intrahepatic cholangiocarcinoma. This causal framing substantially strengthens the argument that these proteases are active participants in tumor biology rather than bystanders.

ADAM8 and ADAM17 are membrane-anchored enzymes known as sheddases, meaning they cleave the extracellular portions of other membrane proteins and release them into the surrounding environment. Among their substrates are signaling molecules and receptors that fuel inflammation, angiogenesis, and cell proliferation. The Notch pathway, which the study implicates as a downstream mediator, is a highly conserved cell-to-cell communication system that governs cell fate decisions; when dysregulated, it can promote tumor growth, epithelial-mesenchymal transition, and resistance to therapy. The idea that blocking ADAM8/17 could simultaneously dampen Notch-driven malignancy gives the target additional mechanistic appeal.

Identifying a target is only half the battle; the harder task is finding a molecule that disables it. Through molecular docking simulations, the team screened for small compounds capable of binding the catalytic machinery of ADAM8/17 and landed on a candidate they designated NY-2. To confirm that the compound genuinely engages its target inside cells rather than merely fitting a computational model, the researchers employed a cellular thermal shift assay. This technique exploits a simple physical principle: proteins stabilized by a bound ligand resist heat-induced denaturation. The assay demonstrated that NY-2 shifts the thermal stability of ADAM8/17 in cells, providing direct biochemical evidence of target engagement, a step that many candidate drugs fail to clear.

With target engagement established, the team moved into functional testing using an impressive battery of models. Patient-derived organoids, miniature three-dimensional tumor cultures grown from actual patient tissue, retain much of the cellular diversity and drug responsiveness of the original tumors, making them a far more faithful testing ground than conventional cell lines. In these organoids, alongside standard MTT proliferation assays, Transwell migration experiments, apoptosis measurements, and cell cycle analyses, NY-2 consistently suppressed the hallmarks of cancer progression: cells stopped dividing, migration was curtailed, and programmed cell death increased. The compound also arrested cells at specific checkpoints in the cell cycle, further choking off tumor expansion.

The mechanistic payoff came from western blotting experiments that mapped exactly which signaling cascades NY-2 disrupts. The results showed that the compound acts through two converging arms. The first is the Notch1–HIF1α–VEGFA axis, a chain in which Notch1 signaling stabilizes the hypoxia-inducible factor HIF1α, which in turn drives vascular endothelial growth factor A production, fueling the blood vessel growth that tumors need to enlarge and spread. The second is the Integrinα5–TGFβ–Smad pathway, in which the adhesion molecule integrin alpha-5 feeds into transforming growth factor beta signaling and its intracellular Smad effectors, a circuit intimately tied to epithelial-mesenchymal transition, the process by which cancer cells acquire invasive and metastatic properties. By suppressing both routes simultaneously, NY-2 attacks the tumor’s growth supply line and its invasion machinery at once.

The clinical significance of these findings is sharpened by the study’s prognostic data, which showed that high ADAM8/17 expression is associated with poor outcomes in patients with intrahepatic cholangiocarcinoma. This dual role, as both a biomarker of aggressive disease and a pharmacologically actionable target, is rare and valuable. It suggests a future in which ADAM8/17 expression levels could help stratify patients most likely to benefit from a targeted inhibitor, moving treatment away from one-size-fits-all chemotherapy toward precision oncology for a cancer that desperately needs it.

The authors are careful to frame this as a foundation rather than a finished therapy. Their stated next steps include gene editing experiments to confirm the target’s necessity and orthotopic liver tumor models, in which tumors are implanted directly into the liver to recreate the organ environment more faithfully than subcutaneous models. Such studies will be essential before any compound derived from NY-2 can approach clinical trials, and the history of cancer drug development is littered with promising preclinical targets that failed to translate. Nevertheless, the breadth of evidence here, spanning population genetics, structural biology, thermal proteomics, and patient-derived models, gives the ADAM8/17 hypothesis unusual depth.

For patients with intrahepatic cholangiocarcinoma, whose five-year survival remains dismal and whose treatment options have barely expanded in decades, the identification of a druggable, causally implicated target with a validated small-molecule inhibitor is a genuinely encouraging signal. The work also exemplifies a modern drug discovery paradigm: computational biology to nominate a target, Mendelian randomization to establish causality, docking and thermal shift assays to validate engagement, and organoids to demonstrate efficacy. If subsequent in vivo studies confirm what this research suggests, ADAM8/17 inhibition could become one of the most closely watched strategies in biliary tract cancer therapeutics.

Subject of Research: The role of ADAM8/17 proteases and the Notch1/Integrinα5 pathway in the development and targeted treatment of intrahepatic cholangiocarcinoma

Article Title: Novel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway

Article References: Yang, K., Han, L., Song, X., Wang, C., Wang, Z., Zhu, Z., Xu, T., Mao, M., Xu, Z., Zhang, Y., & Zhao, Q. (2026). Novel drug target ADAM8/17 is associated with the occurrence of intrahepatic cholangiocarcinoma via Notch1/Integrinα5 pathway. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06616-4

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06616-4

Keywords: intrahepatic cholangiocarcinoma, ADAM8, ADAM17, NY-2 inhibitor, Notch1 signaling, Integrinα5, HIF1α, VEGFA, TGFβ-Smad pathway, Mendelian randomization, patient-derived organoids, targeted therapy

The technique is a hybrid of two established concepts in interventional radiology. Radiation segmentectomy delivers an ablative dose of yttrium-90 glass microspheres directly into the artery feeding the tumor, achieving intense local tumor control. Radiation lobectomy, by contrast, treats the entire tumor-bearing lobe with a moderate dose that induces atrophy of the treated parenchyma, redirecting portal blood flow and growth signals to the untreated lobe, which compensates by enlarging. Modified radiation lobectomy combines these effects in a single procedure: a segmental or two-adjacent-segment boost above 190 Gy for tumor control, layered onto a lobar dose between 80 and 120 Gy to drive hypertrophy of the future liver remnant. In this study, the mean lobar prescribed dose was 198 plus or minus 58 Gy, with a mean segmental boost of 226 plus or minus 153 Gy, and patients received an average of 1.6 segmental doses.

The standard alternative for expanding a future liver remnant is portal vein embolization, which reliably induces hypertrophy but offers no direct tumor treatment, leaving a window during which cancer can progress. Transarterial chemoembolization controls tumors but produces less predictable liver growth and typically requires staged procedures. Modified radiation lobectomy uniquely merges tumor control and remnant augmentation in one session, which is why the researchers at an academic medical center in Colorado turned to it for patients whose tumors were unresectable by imaging criteria or biopsy, who had preserved liver function classified as Child-Pugh A, an Eastern Cooperative Oncology Group performance status of two or less, satisfactory lung shunt fractions, and no extrahepatic disease.

Between January 2019 and April 2022, fifteen consecutive patients underwent the procedure with the intention of bridging to curative resection. The cohort included seven women and eight men with a mean age of 66 years, ranging from 41 to 84. Seven had hepatocellular carcinoma, six of them at intermediate BCLC stage B and one at advanced stage C with portal vein tumor invasion, while eight had intrahepatic cholangiocarcinoma, five of whom had also received neoadjuvant gemcitabine-cisplatin chemotherapy. The mean index tumor size was a formidable 7.8 centimeters, with the largest measuring 16.2 centimeters. All patients had preserved hepatic function, and seven had underlying liver disease, including hepatitis C, alcohol-related injury, and metabolic dysfunction-associated steatotic liver disease.

Treatment planning was individualized through multidisciplinary tumor board discussion and surgical volumetric assessment. Earlier patients underwent planar macroaggregated albumin dosimetry with single-compartment calculations, while later patients benefited from SPECT/CT-based multicompartment personalized dosimetry using dedicated software. In that subgroup, the average perfused tumor absorbed dose reached 576 plus or minus 284 Gy, the average normal tissue dose was 206 plus or minus 95 Gy, the perfused fraction of the liver averaged 63 percent, and the cumulative lung absorbed dose averaged 16.4 Gy. Follow-up with triphasic CT or MRI occurred at one and three months and then at three-month intervals, with volumetric analysis at every time point using the Couinaud methodology and standardized future liver remnant calculations based on body surface area.

The results were remarkable on both fronts. Every one of the fifteen patients showed an objective tumor response by modified RECIST criteria at thirty days, with 40 percent achieving a complete response and 60 percent a partial response; by ninety days, the complete response rate rose to 53 percent as two additional partial responders converted. Meanwhile, the median future liver remnant increased by 12 percent at thirty days and 30 percent at sixty to ninety days. Median standardized future liver remnant climbed from 31 percent at baseline to 36 percent at one month and 40 percent by two to three months. Notably, hypertrophy was similar in cirrhotic and non-cirrhotic patients, and no difference emerged between hepatocellular carcinoma and cholangiocarcinoma, suggesting the volumetric effect is robust across liver conditions and tumor types.

Safety was equally encouraging. There were no major procedure-related complications, no grade three or higher hepatotoxicity by CTCAE version 5.0 criteria, and no cases of cholangitis, cholecystitis, gastric ulcers, pneumonitis, or radiation-induced liver disease. One patient experienced nausea and vomiting lasting ten days, and no patient required extended hospitalization or readmission within thirty days. This favorable profile likely reflects careful selection of patients with preserved baseline liver function and multidisciplinary evaluation, consistent with prior work showing that yttrium-90 treatment of more than 60 percent of the liver can be safe when an adequate functional remnant is maintained.

The surgical conversion rate was the standout finding. Twelve of the fifteen patients, or 80 percent, became technically eligible for curative-intent surgery, a figure substantially higher than the 16 to 20 percent conversion rates reported in earlier modified radiation lobectomy studies. Three patients were excluded by new disease progression in the contralateral liver or lungs, or inadequate remnant growth. Of the twelve eligible patients, one declined surgery and one resection was aborted because cholangiocarcinoma encased the hepatic vein confluence. Ultimately, ten patients underwent major hepatectomy, including four extended right and four standard right hepatectomies and one extended left hepatectomy, or liver transplantation in one case, at a mean of 122 plus or minus 77 days after radioembolization. Every completed resection achieved negative margins, an R0 outcome that is the surgical gold standard.

Pathology revealed a more nuanced picture. Among eight patients with available data, median tumor necrosis was 57.5 percent, ranging from 30 percent to more than 90 percent, and necrosis did not correlate with imaging response or absorbed dose. The authors attribute this variability to large, heterogeneous tumors with uneven microsphere distribution and to the relatively short interval between treatment and explantation. Despite this, overall survival after surgery remained 80 percent. Two patients with cholangiocarcinoma died within days of surgery from infectious complications, while the remaining eight resected patients showed no evidence of recurrence over an average follow-up of 39 months. Median overall survival was 61 months for hepatocellular carcinoma patients but only 19 months for those with cholangiocarcinoma, underscoring that tumor biology, not technical success, remains the dominant determinant of long-term outcome.

The study has clear limitations: it was retrospective, single-center, and small, with heterogeneous dosimetry methods and no comparator group receiving portal vein embolization or chemoembolization. Yet the message is compelling. Modified radiation lobectomy achieved universal tumor response, meaningful remnant hypertrophy, and an 80 percent surgical eligibility rate in patients whose tumors were once deemed unresectable, all with an excellent safety profile. The findings echo larger evidence, including the updated DOSISPHERE-01 analysis and the prospective PROACTIF cohort, showing that patients who reach curative surgery after yttrium-90 therapy enjoy substantially better survival than those managed nonoperatively. Larger prospective trials comparing modified radiation lobectomy with established bridging strategies are still needed, but for carefully selected patients with large primary liver cancers, this single-procedure approach may be transforming the boundary between inoperable and curable.

Subject of Research: Modified yttrium-90 radiation lobectomy as a bridge to curative surgery for primary liver cancer

Article Title: Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes

Article References: Malavia, M., Lindquist, J., Marchak, K., Eliason, G., Trivedi, P., & Casadaban, L. (2026). Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes. CVIR Oncology, 2(1), Article 29. https://doi.org/10.1007/s44343-026-00059-x

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00059-x

Keywords: modified radiation lobectomy, yttrium-90 radioembolization, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, future liver remnant hypertrophy, liver resection, radiation segmentectomy, portal vein embolization, surgical conversion, tumor response, interventional radiology, liver cancer